HarvardX PH125.9x Capstone CYO (Choose Your Own) project -Early autoimmune biomarker for multiple sclerosis

Kicheol Kim

Feb. 5, 2022

Introduction

Multiple sclerosis (MS) is a neurodegenerative autoimmune disease of the central nervous system caused by demyelination. The international multiple sclerosis genetics consortium (IMSGC) identified identified more than 200 independent risk loci in multiple sclerosis through genome-wide association studies. Further studies shown that most of risk loci harbor genes expressed in immune cells such as T cells. Multiple sclerosis have 4 different type of disease course according to the National MS Society. CIS (clinically isolated syndrome) is a first episode of inflammation and demyelination. CIS may or may not go on to develop MS. RRMS (relapsing-remitting MS) is the most common disease course. RRMS experiences neurological attack (relapse/exacerbation) followed by periods of recovery (remission). SPMS (secondary progressive MS) follows initial RR courses. Some RRMS patients will transition to secondary progressive course which is progressive worsening of neurologic function. PPMS (primary progressive MS) is progressive worsening of neurologic function from the onset of the disease.

Kim et al. (2021; PMID 33374005) published post-translational modification in CD4+ T cells is critical in MS pathogenesis. This publication provides CD4+ T cell transcriptome dataset from early diagnosed multiple sclerosis patients. Therefore, in this analysis, I used differential expression analysis and machine learning techniques to identify potential early biomarker for autoimmune response in MS.

The dataset (gene expression) has been downloaded from GEO (Accession No. GSE137143). This dataset includes 3 different cell types (CD4+ T cell, CD8+ T cells, CD14+ monocytes). Since I have interested in CD4+ T cells, I kept only CD4+ cells and removed CD8+ and CD14+ cells.

[1] 138 14

```
##
                   geoID
                                                            title age.at.exam
## 13311d-CD4 GSM4071522
                                    Healthy controls, 13311d-CD4
                                                                            35
## 43213b-CD4 GSM4071526 Treatment naïve MS patients, 43213b-CD4
                                                                            34
## 46913b-CD4 GSM4071529 Treatment naïve MS patients, 46913b-CD4
                                                                           72
## 47413a-CD4 GSM4071535 Treatment naïve MS patients, 47413a-CD4
                                                                           44
## 47513a-CD4 GSM4071538 Treatment naïve MS patients, 47513a-CD4
                                                                            63
## 47713b-CD4 GSM4071541 Treatment naïve MS patients, 47713b-CD4
                                                                            24
                 cell.type disease.duration
                                                       disease.state
## 13311d-CD4 CD4+ T cells
                                                     Healthy control
## 43213b-CD4 CD4+ T cells
                                           O Multiple sclerosis (MS)
## 46913b-CD4 CD4+ T cells
                                          28 Multiple sclerosis (MS)
## 47413a-CD4 CD4+ T cells
                                           2 Multiple sclerosis (MS)
## 47513a-CD4 CD4+ T cells
                                          2 Multiple sclerosis (MS)
## 47713b-CD4 CD4+ T cells
                                          O Multiple sclerosis (MS)
              disease.subtypes edss gender disease.state2
##
                                                             sampleID cell.type2
```

##	13311d-CD4	NA	NA	M	HC	13311d-CD4	CD4
##	43213b-CD4	RR	2.0	F	MS	43213b-CD4	CD4
##	46913b-CD4	SP	2.5	F	MS	46913b-CD4	CD4
##	47413a-CD4	PP	4.0	M	MS	47413a-CD4	CD4
##	47513a-CD4	PP	2.0	F	MS	47513a-CD4	CD4
##	47713b-CD4	RR	2.5	M	MS	47713b-CD4	CD4
##		disease.subtype2	AgeAt	ExamGrp			
##	13311d-CD4	HC		30_40			
##	43213b-CD4	RR		30_40			
##	46913b-CD4	PMS		60_90			
##	47413a-CD4	PMS		40_50			
##	47513a-CD4	PMS		60_90			
##	47713b-CD4	RR		10_30			

Methods and Analysis

1. Download dataset

I have downloaded RSEM outputs from GEO (Acc. No. GSE137143) and decompressed downloaded file. The count matrix created using tximport package.

2. Normalization and differential expression analysis using DESeq2

The gene expression counts were normalized using DESeq2 and transformed by variance stabilization transformation for machine learning model building.

Here, I used differential expression analysis model design like this in the DESeq2:

```
\sim diseaseSubtype + gender + age - 1
```

I would like to compare in disease, and gender and age are covariates. I used all dataset for normalization and dispersion calculation. Since There are 3 different disease courses and healthy controls, I added '- 1' variable to get individual disease subtype and compare between single disease subtype and healthy control.

```
## using counts and average transcript lengths from tximport

## estimating size factors

## using 'avgTxLength' from assays(dds), correcting for library size

## estimating dispersions

## gene-wise dispersion estimates

## mean-dispersion relationship

## final dispersion estimates


## fitting model and testing
```

```
## -- replacing outliers and refitting for 932 genes
## -- DESeq argument 'minReplicatesForReplace' = 7
## -- original counts are preserved in counts(dds)
## estimating dispersions
## fitting model and testing
```

PCA plot and outlier samples PCA plot showed 2 outlier samples in CD4+ T cell samples. Therefore, I removed these outlier samples from the DESeq2 object. Then count data transformed by variance stabilization transformation for further machine learning analysis.

Gene expression of immune cells are affected by gender. In the PCA plot, I observed 2 major clusters that separated by gender. Therefore, gender effect is important in the analysis of immune cells, also critical to use gender as a covariate.

PCA plot with all samples



- ## using pre-existing normalization factors
- ## estimating dispersions
- ## found already estimated dispersions, replacing these
- ## gene-wise dispersion estimates
- ## mean-dispersion relationship

```
## final dispersion estimates

## fitting model and testing


## -- replacing outliers and refitting for 179 genes
## -- DESeq argument 'minReplicatesForReplace' = 7

## -- original counts are preserved in counts(dds)

## estimating dispersions

## fitting model and testing
```

PCA plot without outlier samples



3. Prepare dataset for machine learning

Although some CIS patient may not develop to MS, CIS is beginning of the MS disease course. In addition, there was almost no difference between CIS and RRMS in previous analysis (results does not shown here). Therefore, I performed differential expression analysis between CIS and healthy control to remove noise then used top significant genes for model building.

Next, because I want to compare between CIS and healthy controls, I excluded other disease course samples. Then selected samples were randomly split into training (80%) and test (20%) samples.


[1] 38281 59


I created a function to summarize modeling results of machine learning.


```
## function to retrieve model fitting results
fit_output <- function(fit, test_set, test_set_meta, model_name, gene_n){</pre>
  confusionMatrix <- confusionMatrix(predict(fit, test_set), test_set_meta$disease.subtype2)</pre>
  confusionMatrix
  pred_for_roc <- as.data.frame(predict(fit, test_set, type="prob"))</pre>
  pred_for_roc$predict <- names(pred_for_roc)[1:2][apply(pred_for_roc[,1:2], 1, which.max)]</pre>
  pred_for_roc$observed <- test_set_meta$disease.subtype2</pre>
  roc_obj <- roc(pred_for_roc$observed, as.numeric(pred_for_roc$CIS))</pre>
 ml_res <- data.frame(Method = model_name, NumAnalyte = gene_n,</pre>
                        AUC = auc(roc obj),
                        Accuracy = confusionMatrix$overall["Accuracy"],
                        Sensitivity = confusionMatrix$byClass["Sensitivity"],
                        Specificity = confusionMatrix$byClass["Specificity"],
                        row.names = NULL)
 return(ml res)
}
```

4. Try multiple modeling methods with various number of genes

I have run 5 different modeling methods (lda, rf, glmnet, knn, symlinear) with 10 different number of analytes (100 genes ~ 1000 genes).







##		Method	NumAnalyte	AUC	Accuracy	Sensitivity	Specificity
##	1	rf	•		0.9166667	1	0.75
##	2	rf	300	0.968750	0.9166667	1	0.75
##	3	rf	400	0.968750	0.9166667	1	0.75
##	4	rf	100	0.937500	0.9166667	1	0.75
##	5	rf	500	0.968750	0.8333333	1	0.50
##	6	rf	600	0.968750	0.8333333	1	0.50
##	7	rf	800	0.937500	0.8333333	1	0.50
##	8	rf	900	0.921875	0.8333333	1	0.50
##	9	rf	700	0.906250	0.8333333	1	0.50
##	10	rf	1000	0.906250	0.8333333	1	0.50
##	11	knn	200	0.843750	0.3333333	0	1.00
##	12	lda	200	0.812500	0.3333333	0	1.00
##	13	lda	300	0.781250	0.3333333	0	1.00
##	14	lda	800	0.750000	0.3333333	0	1.00
##	15	lda	600	0.718750	0.3333333	0	1.00
##	16	lda	1000	0.718750	0.3333333	0	1.00
##	17	knn	1000	0.687500	0.3333333	0	1.00
##	18	lda	900	0.656250	0.3333333	0	1.00
##	19	knn	800	0.593750	0.3333333	0	1.00
##	20	lda	400	0.562500	0.3333333	0	1.00
##	21	knn	600	0.562500	0.3333333	0	1.00
##	22	lda	700	0.562500	0.3333333	0	1.00
##	23	lda	500	0.531250	0.3333333	0	1.00
##	24	${\tt glmnet}$	100	0.500000	0.3333333	0	1.00
##	25	knn	100	0.500000	0.3333333	0	1.00

##	26	svmLinear2	100	0.500000	0.3333333	0	1.00
##	27	glmnet	200	0.500000	0.3333333	0	1.00
##	28	${\tt svmLinear2}$	200	0.500000	0.3333333	0	1.00
##	29	glmnet	300	0.500000	0.3333333	0	1.00
##	30	knn	300	0.500000	0.3333333	0	1.00
##	31	${\tt svmLinear2}$	300	0.500000	0.3333333	0	1.00
##	32	glmnet	400	0.500000	0.3333333	0	1.00
##	33	knn	400	0.500000	0.3333333	0	1.00
##	34	${\tt svmLinear2}$	400	0.500000	0.3333333	0	1.00
##	35	glmnet	500	0.500000	0.3333333	0	1.00
##	36	knn	500	0.500000	0.3333333	0	1.00
##	37	${\tt svmLinear2}$	500	0.500000	0.3333333	0	1.00
##	38	glmnet	600	0.500000	0.3333333	0	1.00
##	39	${\tt svmLinear2}$	600	0.500000	0.3333333	0	1.00
##	40	glmnet	700	0.500000	0.3333333	0	1.00
##	41	knn	700	0.500000	0.3333333	0	1.00
##	42	${\tt svmLinear2}$	700	0.500000	0.3333333	0	1.00
##	43	glmnet	800	0.500000	0.3333333	0	1.00
##	44	${\tt svmLinear2}$	800	0.500000	0.3333333	0	1.00
##	45	glmnet	900	0.500000	0.3333333	0	1.00
##	46	knn	900	0.500000	0.3333333	0	1.00
##	47	${\tt svmLinear2}$	900	0.500000	0.3333333	0	1.00
##	48	glmnet	1000	0.500000	0.3333333	0	1.00
##	49	${\tt swmLinear2}$	1000	0.500000	0.3333333	0	1.00
##	50	lda	100	0.343750	0.3333333	0	1.00

5. Model building with best model and number of genes


Based on previous test modeling, random forest method with 100 genes showed best performance. Therefore, I repeat modeling using random forest with 100 top statistically significant genes. In the current random forest run, I used 5-fold cross validation in the modeling because data size is small. The random split cannot reflect heterogeneity of human samples with small dataset.

Results

1. Results of differential expression analysis


In the differential expression analysis, I've found 1044 statistically significant genes (adjusted p-value < 0.1; 415 up-regulated and 629 down-regulated in MS). The heatmap shows top 100 differentially expressed genes (DEG). I observed separation between healthy controls and MS.

```
##
## out of 38280 with nonzero total read count
## adjusted p-value < 0.1
## LFC > 0 (up) : 415, 1.1%
## LFC < 0 (down) : 629, 1.6%
## outliers [1] : 44, 0.11%
## low counts [2] : 17785, 46%
## (mean count < 4)
## [1] see 'cooksCutoff' argument of ?results
## [2] see 'independentFiltering' argument of ?results</pre>
```




2. Results of random forest modeling

In the modeling using random forest with 100 genes, accuracy was 0.8983051 and AUC was 0.9615385. Results details are below:




Importance scores of genes in the model




3. Comparison between differentially expressed genes (DEG) and random forest results

I compared between adjusted p-value from differential expression analysis and imporance score from random forest. This plot indicates differentially expression result and random forest modeling are not consistent. Some genes are shows very low adjusted p-value from differential expression analysis but not well performed in random forest, or vice versa.



Last, these boxplots are examples for expression of top 6 gene that selected based on random forest importance score.



Conclusion

Multiple sclerosis (MS) is autoimmune condition of the central nervous system. In this study, I analyzed peripheral CD4+ T cells using differential expression analysis method and machine learning to identify early autoimmune response biomarker for MS. I found 1044 differential expressed genes in CIS and used statistically significant genes for model building using the random forest method. The final model achieved AUC 0.9615385 and accuracy 0.8983051 using 100 genes.

The genes identified in this study are potential early biomarker for multiple sclerosis that could detect neurological attack from blood. In addition, pathways associated with these genes in immune cells might be potential biomarker or therapeutic target for autoimmunity in CD4+ T cells in MS.

As shown in the PCA plot, the immune cells have strong gender effect. Therefore, I selected top differential expressed genes that tested with gender and age as a covariate in the current study. However, the performance could improve with adjustment of gender effect in the model building.